Richter’s Biosimilar Costs ‘Took Up A Lot Of Resources Last Year’

Growth For Teriparatide Biosimilar Terrosa Expected To Slow In 2022

 
• By Dean Rudge
  
Watering_Plant
Richter praised its licensing deal with Hikma • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products